Methods for treating arenaviridae and coronaviridae virus infections
Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
1. A method of treating a Coronaviridae infection in a human in need thereof, comprising administering to the human a therapeutically effective amount of a compound having formula:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , comprising administering to the human a therapeutically effective amount of a compound having formula:
3. The method of claim 1 , further comprising administering a pharmaceutically acceptable carrier or excipient.
4. The method of claim 1 , further comprising administering a therapeutically effective amount of at least one other therapeutic agent.
5. The method of claim 4 , wherein the at least one other therapeutic agent is selected from the group consisting of a corticosteroid, an anti-inflammatory signal transduction modulator, β2-adrenoreceptor agonist bronchodilator, an anticholinergic, a mucolytic agent, hypertonic saline, and other drugs for treating a Coronaviridae virus infection; or mixtures thereof.
6. The method of claim 1 , wherein the Coronaviridae infection is caused by a Coronaviridae virus selected from the group consisting of SARS, MERS, 229E, NL63, OC43, and HKU1.
7. The method of claim 1 , wherein the Coronaviridae infection is caused by a SARS virus.
8. The method of claim 1 , wherein the Coronaviridae infection is caused by a MERS virus.
9. The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered by oral, rectal, nasal, pulmonary, topical, vaginal, or parenteral administration.
10. The method of claim 9 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered by parenteral administration.
11. The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered by subcutaneous, intramuscular, intravenous, intradermal, intrathecal, or epidural administration.
12. The method of claim 11 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered by intravenous administration.
13. The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered by inhalation administration.